ALC241220P87500
- 3.32
- 0.000.00%
Alcon Newsroom
UBS Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $105.57
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)
Needham Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $108
Alcon Is Maintained at Buy by Needham
Alcon Analyst Ratings
UBS Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $107.55
Analysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), Alcon (ALC)
UBS Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $107.25
Deutsche Bank Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $92.9
J.P. Morgan Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $89.5
Analysts Conflicted on These Healthcare Names: Alcon (ALC), Innate Pharma SA (OtherIPHYF) and ScPharmaceuticals (SCPH)
BofA Securities Maintains Alcon(ALC.US) With Hold Rating, Cuts Target Price to $93.63
Jefferies Maintains Alcon(ALC.US) With Buy Rating, Cuts Target Price to $100
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $93.63 to $107
KeyBanc Sticks to Their Buy Rating for Alcon (ALC)
Alcon's Strong Market Position and Growth Prospects Underscore Buy Rating
A Quick Look at Today's Ratings for Alcon(ALC.US), With a Forecast Between $97.06 to $107
Alcon's Mixed Q3 Performance and Product Pipeline Drive Hold Rating
Alcon Analyst Ratings
Alcon's Strategic Growth Potential and Market Position Justify Buy Rating